Surrozen (SRZN)
(Delayed Data from NSDQ)
$8.44 USD
-0.56 (-6.22%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $8.40 -0.04 (-0.47%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SRZN 8.44 -0.56(-6.22%)
Will SRZN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for SRZN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRZN
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards? (Revised)
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
SRZN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
Here's Why Surrozen, Inc. (SRZN) Could be Great Choice for a Bottom Fisher
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?
Other News for SRZN
Surrozen Publishes Study in ‘eLife’ Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling
Surrozen publishes study in 'eLife' on the proprietary SWEETS platform
Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan
Surrozen presents preliminary results from Phase 1a study of SZN-043
Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis